ATLANTA, GA – – (Newsfile Corp. – November 3, 2020) – – Holzer & Holzer, LLC is investigating whether Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) complied with federal securities laws. On October 28, 2020, the Company announced that the FDA voted on its Neovasc Reducer and found against issuing a reasonable assurance of effectiveness and against whether the benefits outweigh the relative risks. The price of Neovasc’s stock fell following the announcement. If you purchased shares of Neovasc and suffered a loss on that investment, you are encouraged to contact Marshall P. Dees, Esq. at email@example.com or Luke R. Kennedy, Esq. at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.